PL2424529T3 - Nowe postępowania terapeutyczne z zastosowaniem centakwiny - Google Patents

Nowe postępowania terapeutyczne z zastosowaniem centakwiny

Info

Publication number
PL2424529T3
PL2424529T3 PL10770318T PL10770318T PL2424529T3 PL 2424529 T3 PL2424529 T3 PL 2424529T3 PL 10770318 T PL10770318 T PL 10770318T PL 10770318 T PL10770318 T PL 10770318T PL 2424529 T3 PL2424529 T3 PL 2424529T3
Authority
PL
Poland
Prior art keywords
centhaquin
therapeutic treatments
novel therapeutic
treatments
novel
Prior art date
Application number
PL10770318T
Other languages
English (en)
Polish (pl)
Inventor
Anil Gulati
Original Assignee
Midwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Midwestern University filed Critical Midwestern University
Publication of PL2424529T3 publication Critical patent/PL2424529T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
PL10770318T 2009-04-30 2010-04-29 Nowe postępowania terapeutyczne z zastosowaniem centakwiny PL2424529T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17425709P 2009-04-30 2009-04-30

Publications (1)

Publication Number Publication Date
PL2424529T3 true PL2424529T3 (pl) 2017-06-30

Family

ID=43032771

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10770318T PL2424529T3 (pl) 2009-04-30 2010-04-29 Nowe postępowania terapeutyczne z zastosowaniem centakwiny

Country Status (10)

Country Link
US (2) US20120083447A1 (enExample)
EP (1) EP2424529B1 (enExample)
JP (2) JP5498571B2 (enExample)
CN (2) CN102458399B (enExample)
AU (1) AU2010241564B2 (enExample)
BR (1) BRPI1013903B1 (enExample)
CA (1) CA2759791C (enExample)
ES (1) ES2614813T3 (enExample)
PL (1) PL2424529T3 (enExample)
WO (1) WO2010127096A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5498571B2 (ja) 2009-04-30 2014-05-21 ミッドウェスタン ユニバーシティ センタキンを用いた新規の治療方法
CN110354267A (zh) * 2012-08-31 2019-10-22 法尔麦兹公司 用于低血压复苏的方法和组合物
WO2016061583A1 (en) * 2014-10-17 2016-04-21 University Of Virginia Patent Foundation Compositions and methods for treating pituitary tumors
JP7458032B2 (ja) * 2018-05-03 2024-03-29 ミッドウェスタン ユニバーシティ 出血およびセンタキンによる蘇生後のエンドセリン受容体の変化
CN117440812A (zh) * 2021-05-11 2024-01-23 法尔麦兹公司 用于治疗冠状病毒病(covid-19)中的急性呼吸窘迫综合征(ards)的药物组合物及方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954987A (en) * 1972-12-22 1976-05-04 Sandoz, Inc. 2-Alkyl-4-substituted amino-quinazolines and nitrates thereof in the treatment of myocardial shock
DE2421382A1 (de) 1974-05-03 1975-11-20 Council Scient Ind Res 1-substituierte 4-(beta-2-chinolylaethyl)- piperazine und deren 1,2,3,4-tetrahydrochinolinanaloge
JPS604186B2 (ja) 1974-05-13 1985-02-01 カウンシル、オブ、サイエンテイフイツク、アンド、インダストリアルリサーチ １―ｍ―トリル―４―（Ｂ―２―キノリエチル）―ピペラジンの製造法
US3983121A (en) 1974-07-01 1976-09-28 Council Of Scientific And Industrial Research 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof
DE2557784C2 (de) * 1975-12-22 1986-04-17 Hoechst Ag, 6230 Frankfurt Forskolin, Verfahren zu dessen Gewinnung und diese Verbindung enthaltende pharmazeutische Präparate
US4761417A (en) * 1982-05-14 1988-08-02 Maroko Peter R Compounds, compositions and method of treatments for improving circulatory performance
EP0126327A1 (en) 1983-04-26 1984-11-28 Frank J. Macri Norepinephrine potentiated pharmaceutical composition, ophthalmic solution and kit containing the same
US5055470A (en) 1989-06-01 1991-10-08 Bristol-Myers Squibb Co. Method of treatment of ischemia in brain
US5922681A (en) 1992-09-14 1999-07-13 Warner-Lambert Company Endothelin antagonists
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6369114B1 (en) 1999-11-30 2002-04-09 Institute Of Critical Care Medicine Administration of an α2-adrenergic receptor agonist to enhance cardiopulmonary resuscitation
GB0013378D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
SE0004455D0 (sv) 2000-12-01 2000-12-01 Milos Pekny Method for neuron regeneration in the central nervous system
WO2002049630A2 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
US20030232787A1 (en) 2001-05-08 2003-12-18 Dooley David James Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
US20030104976A1 (en) 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
US7030082B2 (en) 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7973064B2 (en) * 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
US7351692B2 (en) * 2002-06-19 2008-04-01 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating the antipyretic action of a nonopioid analgesic
JP2006508086A (ja) 2002-10-24 2006-03-09 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 固形腫瘍を予防および治療するための方法および組成物
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
DK1583541T3 (da) 2002-11-20 2011-04-11 Neuronova Ab Forbindelser og fremgangsmåder til at øge neurogenese
CN101005828B (zh) 2004-06-17 2012-01-11 维尔恩公司 用于经粘膜递送活性成分的包含粘膜粘附蛋白和所述活性物质的组合物
WO2008043102A2 (en) 2006-10-06 2008-04-10 Transition Therapeutics Inc. Vasoactive intestinal polypeptide compositions
EP1931199A4 (en) 2005-08-31 2009-07-29 Univ Tennessee Res Foundation COMBATING NURSE DISEASE, BURNS, WOUNDS AND BACKMARK INJURIES WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS
JP4976412B2 (ja) 2005-12-01 2012-07-18 ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法
AU2007230887A1 (en) 2006-03-23 2007-10-04 Amylin Pharmaceuticals, Inc. Endothelin and endothelin receptor agonists in the treatment of metabolic diseases
CA2696398C (en) 2007-08-21 2018-05-08 Midwestern University Methods for treatment of stroke or cerebrovascular accidents using an etb receptor agonist
US20100189802A1 (en) 2007-08-21 2010-07-29 Scott And White Memorial Hospital And Scott, Sherwood, And Brindley Foundation Method for treatment of vascular hyperpermeability
CN101374259B (zh) 2007-08-22 2012-08-08 华为技术有限公司 实现多媒体彩铃和多媒体彩像业务的方法和装置
EP2165706A1 (en) 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
JP5498571B2 (ja) 2009-04-30 2014-05-21 ミッドウェスタン ユニバーシティ センタキンを用いた新規の治療方法
BRPI1013904A2 (pt) 2009-04-30 2016-07-19 Univ Midwestern método e composição para tratar cetoacidose diabética
WO2011159854A1 (en) 2010-06-17 2011-12-22 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of ccr2
KR101418941B1 (ko) 2011-04-04 2014-07-15 서울대학교병원 엔도텔린을 유효성분으로 함유하는 허혈성질환 치료용 조성물
CN110354267A (zh) 2012-08-31 2019-10-22 法尔麦兹公司 用于低血压复苏的方法和组合物
ES2825101T3 (es) 2013-07-08 2021-05-14 Univ Midwestern Composiciones y métodos para el tratamiento de trastornos neuropsiquiátricos usando un agonista del receptor de la endotelina B
JP7458032B2 (ja) 2018-05-03 2024-03-29 ミッドウェスタン ユニバーシティ 出血およびセンタキンによる蘇生後のエンドセリン受容体の変化

Also Published As

Publication number Publication date
US10828368B2 (en) 2020-11-10
ES2614813T3 (es) 2017-06-02
JP5727642B2 (ja) 2015-06-03
US20120083447A1 (en) 2012-04-05
US20180085461A1 (en) 2018-03-29
EP2424529B1 (en) 2016-12-28
CN102458399B (zh) 2014-04-23
BRPI1013903B1 (pt) 2020-03-03
EP2424529A4 (en) 2012-11-28
JP2012525422A (ja) 2012-10-22
EP2424529A2 (en) 2012-03-07
CN102458399A (zh) 2012-05-16
WO2010127096A3 (en) 2011-03-24
AU2010241564A1 (en) 2011-11-17
BRPI1013903A2 (pt) 2016-07-19
CN103989682A (zh) 2014-08-20
WO2010127096A2 (en) 2010-11-04
CA2759791C (en) 2018-04-10
AU2010241564B2 (en) 2014-07-31
CN103989682B (zh) 2016-03-30
JP5498571B2 (ja) 2014-05-21
CA2759791A1 (en) 2010-11-04
JP2014141502A (ja) 2014-08-07
AU2010241564A2 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
GB0908957D0 (en) Therapeutic agents
GB0900461D0 (en) Photodynamic therapy device
GB0900599D0 (en) Treatment
GB0900484D0 (en) Therapeutic agent
GB201013898D0 (en) Well treatment
BRPI1013903A2 (pt) tratamentos terapêuticos utilizando centaquina
GB0913968D0 (en) Treatment
GB0916997D0 (en) Combination therapy
GB201001521D0 (en) Treatment
GB0907973D0 (en) Combination therapy
GB0910493D0 (en) Therapeutic agents
GB0906026D0 (en) Therapeutic compounds
GB0915802D0 (en) Therapeutic treatments
GB0816301D0 (en) Therapeutic treatments
GB0816300D0 (en) Therapeutic treatments
GB0922098D0 (en) Therapeutic use
GB0914820D0 (en) WATerian therapy
GB0903319D0 (en) Therapy
GB0921244D0 (en) Therapy
GB0903321D0 (en) Therapy
GB201014918D0 (en) Therapeutic treatments
GB201014917D0 (en) Therapeutic treatments
GB0904261D0 (en) New therapeutic use
GB0914533D0 (en) Therapeutic agents
GB0919821D0 (en) Therapeutic agents